San Diego biotech Singlera Genomics said the FDA has granted Breakthrough Device Designation for its new assay, which detects deadly pancreatic ductal adenocarcinoma in high-risk patients.
Sign up for our daily digest of everything you need to know about San Diego — just the essentials, every morning.
By clicking sign up, you agree to the terms.
San Diego biotech Singlera Genomics said the FDA has granted Breakthrough Device Designation for its new assay, which detects deadly pancreatic ductal adenocarcinoma in high-risk patients.
